Chongqing Zyscin Pharmaceutical Technology Co., Ltd.

CHONGQING ZYSCIN PHARMACEUTICAL TECHNOLOGY COPORATION, LTD. founded in Jan. 2020. The headquarter of the company is located at Dadi International Biotechnology Park, Liangjiang new district, Chongqing, China. The total construction area is 2000m2 with R&D and Administration. In October 2021, ZYSCIN acquired Jiangxijuhe Pharmaceutical Technology Co. Ltd. as production site with 340 M3 production capacity. RTO, MVR and sewage station ensure production safety and sustainability. Ensure the compliance of EHS system operation through internal and external audit at regular intervals. The company passed the ISO9001 quality management system certification and obtained the certificate and passed the quality audit of Huahai, AMI, Aurobindo, Jiangxi Porton and Mitsuko Corporation. The company not only focuses on the cardiovascular drugs, Antiviral drugs and anti-tumor drugs, but also pays more attention to the CRO, CDMO and CMO service. Products: -Darunavir intermediates -Adagrasib intermediates -Isavuconazole intermediates -Vonapraza intermediates -Upadacitinib intermediates -Abiraterone intermediates -Torasemide intermediates -Paxlovid intermediates -Flame retardants intermediateNebivolol intermediates -Raw materials of Aesthetic medicine